<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tblu24" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Groups</th><th valign="top">F test statistic</th><th valign="top">Partial &#951;<sup>2</sup></th><th valign="top">Effect size <italic>f</italic></th><th valign="top">A priori <break/>power</th><th valign="top">Total <break/>sample size</th></tr></thead><tbody><tr><td valign="top">Drug-na&#239;ve PC9 cells and PC9 <break/>DTPs left untreated <break/>or treated with <break/>TSA (50 nM or 100 nM)</td><td valign="top">F(2,12) = 9.3683 <break/>(interaction)</td><td valign="top">0.60959</td><td valign="top">1.24956</td><td valign="top">84.7%<sup>1</sup></td><td valign="top">12<sup>1</sup> <break/>(6 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p><sup>1</sup> 18 total samples (3 per group) will be used based on the planned comparisons making the power 99.0%.</p></fn></table-wrap-foot></table-wrap>